CNCE NASDAQ
Concert Pharmaceuticals, Inc.
1W: -0.1%
1M: -0.2%
3M: +73.7%
1Y: +171.8%
3Y: -12.0%
5Y: -60.2%
$8.37
Last traded 2023-03-03 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$33M
+312.3% ▲
5Y CAGR: +184.8%
Gross Profit
$33M
+312.3% ▲
5Y CAGR: +184.8%
Operating Income
-$78M
-6.7% ▼
Net Income
-$83M
-10.5% ▼
EPS (Diluted)
$-2.40
+0.0% ▲
EBITDA
-$73M
-6.8% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $144M | $11M | $1M | $8M | $33M |
| YoY Growth | +82596.0% | -92.7% | -89.7% | +633.7% | +312.3% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $144M | $11M | $1M | $8M | $33M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D Expenses | $30M | $43M | $60M | $62M | $88M |
| SG&A Expenses | $21M | $23M | $20M | $19M | $22M |
| Operating Expenses | $51M | $66M | $80M | $81M | $110M |
| Operating Income | $93M | -$56M | -$79M | -$73M | -$78M |
| Operating Margin | 64.4% | -529.1% | -7336.6% | -919.3% | -237.9% |
| Interest Expense | $815K | -$127K | $0 | $0 | $0 |
| Income Before Tax | $95M | -$56M | -$78M | -$75M | -$80M |
| Tax Expense | -$300K | $313K | -$837K | -$85K | $3M |
| Net Income | $96M | -$56M | -$77M | -$75M | -$83M |
| Net Margin | 66.5% | -533.3% | -7180.0% | -946.2% | -253.5% |
| EPS (Diluted) | $4.08 | $-2.40 | $-3.26 | $-2.40 | $-2.40 |
| EBITDA | $97M | -$54M | -$78M | -$69M | -$73M |
| Shares Outstanding | 23M | 23M | 24M | 31M | 34M |